Heterogeneity in Treatment Effects of Reduced Versus Standard Dose of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer.

ABSTRACT:

Background

In the PROSELICA, a randomized controlled trial (RCT) comparing cabazitaxel 20 mg/m² (C20) versus 25 mg/m² (C25) in metastatic castration-resistant prostate cancer (mCRPC), one-variable-at-a-time subgroup analysis suggested possible heterogeneity in treatment effect (HTE) of C25 versus C20 among study participants. Novel predictive HTE analysis approaches may provide an in-depth understanding of such results.

Methods

We analyzed patient-level data from 1200 patients with mCRPC who were randomized in the PROSELICA trial. Outcomes included overall survival (OS) and progression-free survival (PFS). Using baseline characteristics, patients were stratified into quartiles based on either quantitative baseline risk of poor outcome (risk modeling) or

SUBMITTER: Fukuokaya W 

PROVIDER: S-EPMC12788979 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature